Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.
Stock Quote NH (Common Stock) $9.91 - 0.01 (0.00%)
Today's Open$10.05
Previous Close$9.91
Data as of 12/07/16 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NH.O.  Currently trading at $9.91 with a 52 week high of $21.00 and a 52 week low of $9.61.
Recent News

December 07, 2016

NantHealth And TransMed Systems Partner to Enable and Inform Community Oncologists of the Most Effective Tools and Technologies for Personalized Cancer Treatments Using GPS Cancer™

Collaboration will provide access to data around real-time outcomes including clinical trial matches and cost analysis to the network of community cancer centers treating patients with rare and common cancers CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 7, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company and TransMed Systems, a company that develops and deploys software solu...

Read More >

December 06, 2016

NantHealth Announces Exclusive Reseller Agreement for GPS Cancer™ with Oncotest-Teva in Israel

Company continues strong momentum for its comprehensive molecular test for cancer care and driving the era of clinical proteomics by landing first international distributor relationship CULVER CITY, Calif. & SHOHAM, Israel--(BUSINESS WIRE)--Dec. 6, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has entered into an exclusive reseller agreement for GP...

Read More >

December 05, 2016

NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Molecular Profiling to Patients in the Middle East Through Partnership with Lunatus

Oncologists in United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon will be empowered to make more informed clinical decisions to personalize treatment and care for their patients Partnership builds on international expansion of GPS Cancer which was recently made available in Italy and Israel CULVER CITY, Calif. & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Dec. 5, 2016-- NantHealth, Inc., (Nasdaq: NH), a...

Read More >

Upcoming Events
There are currently no events scheduled.